November 15, 2025, Innovative Bone Repair MaterialsSmartbone® China Launch ConferenceSuccessfully held during COA 2025 in Tianjin. This is an important milestone for Susheng Biotech in advancing bioactive bone materials. The launch event brought together numerous orthopedic experts and industry guests to witness the grand unveiling of Smartbone®.
Authoritative EndorsementIn-Depth Interpretation of Product Value by International ScholarsAt this press conference, the company also specially invited a well-known scholar from Switzerland,IBIDr. Gianni Pertici, the founder, visited Susheng Biotech's booth and delivered an in-depth presentation on Smartbone®.
Renowned Swiss scholar in bone materials, Co-founder of IBI Company
Dr. Gianni Perticci Live Sharing
As an internationally renowned expert in this technical field,Dr. Perticci delves into the product's design concept, core technology, and global application experience.His sharing provides a solid academic endorsement for the launch of Smartbone® in China and helps clinicians understand the clinical value of the product at a deeper level.
Dr. Gianni Perticchi stated that the naming of Smartbone® signifies the perfect combination of "intelligence" and "bone." It is not just a product, but an intelligent solution we are bringing to Chinese clinicians and patients.Its excellent osteogenic performance and operational convenience will effectively meet the clinical demand for efficient and safe bone repair materials.
At the same time, excellent material properties combined with digital orthopedic technology enable precise 3D customization, providing a brand-new solution for the regeneration needs of large-volume bone defects in multiple parts.
Smartbon® Bone Material Key Features:
• Strong osteogenic ability
• Good biocompatibility
• High Toughness and High Strength
• Malleable
• Affordable
The Way to Break the StalemateSolve the Three Major Bottlenecks of Bone TransplantationDr. Zeng Sheng, Chairman of Susheng Biotech, stated:
The launch of Smartbone® in China marks a critical step for Susheng Biotech in the field of composite bioactive bone, aiming to address the three long-standing bottlenecks faced by bone graft materials: "limited sources, insufficient performance, and ethical constraints." Currently, while autologous bone grafting is regarded as the gold standard, its availability is limited; allogeneic bone, on the other hand, is constrained by donor shortages and regulatory ethical restrictions. The market has yet to see an artificial bone material capable of fully simulating the structure and function of human bone.
The emergence of Smartbone® is expected to change this situation. It features a highly biomimetic microstructure of human bone, high-strength mechanical properties, high hydrophilicity, and is loaded with a unique RGD (arginine-glycine-aspartic acid) sequence protein, effectively promoting osteogenesis.While retaining the advantages of "autologous bone" and "allogeneic bone," it overcomes their limitations in terms of source and ethical concerns.At the same time, excellent material properties combined with digital orthopedic technology enable precise 3D customization, providing a new solution for the regeneration needs of large-volume bone defects in multiple parts.
For many years, Susheng Biotech has adhered to high-level research, development, and innovation, guided by genuine needs. The company has focused on bone grafts, tissue-engineered artificial cartilage, and sports medicine implantable medical device products. The successful launch of Smartbone® marks an important achievement for Susheng Biotech in combining international advanced technology with clinical needs in China. This demonstrates the company’s strong R&D transformation capabilities and market insight. In the future, Susheng Biotech will continue to push for the implementation of more products and solutions, fulfilling its mission to improve patients' quality of life and contributing to the advancement of orthopedic technology in China.
Continuous Innovation, Helping Chinese Orthopedics Achieve a Leap ForwardUnder the joint witness of all guests, Smartbone® was officially launched, showcasing Susheng Biotech's long-term commitment to addressing real clinical needs and its unwavering dedication to the development, technology, and innovation of orthopedic materials.
The listing ceremony has successfully concluded, but the development and innovation of bone materials will not stop. It is believed that in the future, Susheng Biotech's Smartbone® bone materials and more orthopedic products will become an important driving force for academic innovation and clinical practice, helping China's orthopedics achieve a leap from "running alongside" to "taking the lead."
